Clinical trials: Human Papilloma Virus Infection
Human Papillomavirus Infection
A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine
This study is to demonstrate that the administration of the investigational vaccine can reduce the Combined Incidence of HPV types 6/11/16/18/31/33/45/52/58-related high-grade Cervical Intraepithelial Neoplasia (CIN 2/3)…
- Trial name
- NCT05668572
- Testing
- Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）
- Where
- 3 sites in China
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Cervical Carcinoma, Human Papillomavirus Infection
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention.
- Trial name
- NCT07281430
- Testing
- Biospecimen Collection, Cervical Biopsy, Colposcopy
- Where
- 18 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Infections, Papillomavirus
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years
Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. The infection of the cervix by certain oncogenic types of HPV, if not cleared, can lead to cervical cancer in women.
- Trial name
- NCT00485732
- Testing
- HPV-16/18 VLP/AS04 vaccine (Cervarix TM)
- Where
- 6 sites in South Korea
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccination Refusal, Opinions
Children Vaccination From 11 to 14 Years Old
The human papilloma virus infection is the most frequent sexually transmitted infection around the world. In the vast majority of cases, these are inapparent infections that disappear spontaneously.
- Trial name
- QUALIOPIVAC (NCT04871243)
- Testing
- Qualitative Interview
- Where
- France
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Eure-Seine
Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16
PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia
The purpose of this Phase 2 study is to compare the effects of administering the PVX4 combination device biologic product (pBI-4 DNA vaccine via electroporation-mediated intramuscular delivery with the TriGrid™ Delivery System)…
- Trial name
- NCT07454915
- Testing
- PVX4 Combination Product
- Where
- 10 sites in United States, Taiwan
- Volunteers
- 138 people
- Sponsor
- PapiVax Biotech, Inc.
Human Papilloma Virus Infection, Carcinoma in Situ of Uterine Cervix
Community-Driven Cervical Cancer Prevention in Western Kenya
There are many challenges to implementation of cervical cancer prevention in resource-limited countries, despite evidence based screening and treatment strategies.
- Trial name
- NCT02124252
- Testing
- Community-based testing with standard linkage to care, Community-based HPV testing with enhanced linkage to care
- Where
- Kenya
- Volunteers
- 7,200 people, healthy volunteers welcome
- Sponsor
- Duke University
Chronic Kidney Disease
Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease
People with chronic kidney disease are known to have immune response abnormalities, including a diminished response to some vaccinations.
- Trial name
- NCT00806676
- Testing
- Gardasil® Vaccine (FDA-approved vaccination regimen)
- Where
- 2 sites in United States
- Volunteers
- 67 people
- Sponsor
- Johns Hopkins University
Condylomata Acuminata
Peginterferon α-2b Combined CO2 Laser in Condylomata Acuminata
This is a prospective, randomized, open-label, controlled study, aiming to enroll 30 patients with Condylomata Acuminata. The study consists of two phases: a treatment phase (Weeks W1-W12) and an observation phase (Weeks…
- Trial name
- NCT06430190
- Testing
- Peginterferon α-2b injection, CO2 laser
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhangyu Bu
Infections, Papillomavirus
Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women
The purpose of this phase IIB MedImmune-sponsored study was to evaluate the efficacy of the HPV-16/18 VLP vaccine in the prevention of infection with HPV-16 and/or HPV-18 in adolescent and young adult women.
- Trial name
- NCT00689741
- Testing
- Cervarix
- Volunteers
- 1,113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Hypopharynx
Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer
This phase II trial studies how well paclitaxel and carboplatin before radiation therapy with paclitaxel works in treating human papillomavirus (HPV)-positive patients with stage III-IV oropharynx, hypopharynx, or larynx cancer.
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT02048020
- Testing
- paclitaxel, carboplatin, intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Condylomata Acuminata
Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
This phase I clinical study was designed to evaluate the safety and immunogenicity of the novel recombinant HPV type 6/11 bivalent vaccine, manufactured by Xiamen Innovax Biotech CO., LTD., in healthy volunteers aged over 18-55…
- Trial name
- NCT02405520
- Testing
- low dosage HPV Vaccine, medium dosage HPV Vaccine, high dosage HPV Vaccine
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
HPV Infection
HPV Prevalence in 16-20 Year Old Males
In Quebec, 18 birth cohorts of girls were vaccinated against HPV (aged 9 to 29 years in 2020). With an observed vaccination coverage of >80% an important herd effect might be expected.
- Trial name
- NCT04297670
- Testing
- Measurement of HPV types prevalence
- Where
- Canada
- Volunteers
- 681 people, healthy volunteers welcome
- Sponsor
- Laval University
Infections, Papillomavirus
Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)
This study is designed to evaluate the immunogenicity and safety of GSK Biologicals' human papillomavirus (HPV) vaccine in adult female subjects aged 26-45 years.
- Trial name
- NCT01277042
- Testing
- GSK580299 (CervarixTM), Engerix-BTM
- Where
- China
- Volunteers
- 1,212 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Genital Human Papilloma Virus Infection
AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections
This study aims to prove that, by a one-time topical spray on the cervix, AV2-DM is an effective antiviral in reducing on short term (3 months) the human papillomavirus (HPV) infection.
- Trial name
- NCT01654822
- Testing
- topical application cervical spray, topical spray on the cervix, cervical swab with Cervex-Brush-Combi at T0
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Cesa Projects International
Dose Schedule Study
Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil
To demonstrate that Gardasil® vaccine, when given to girls 11-13 years of age according to 1 of 3 alternative 3-dose schedules (0, 3, 9 months; 0, 6, 12 months; or 0, 12, 24 months), results in anti-HPV type 16 and anti-HPV type…
- Trial name
- NCT00524745
- Testing
- Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
- Where
- Vietnam
- Volunteers
- 903 people, healthy volunteers welcome
- Sponsor
- PATH
Anal Intraepithelial Neoplasia, Anal Cancer
HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL
Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) worldwide. Infection by certain high-risk oncogenic types of HPV (HR-HPV) is the major cause of several cancers in men, notably squamous cell…
- Conditions
- Anal Intraepithelial Neoplasia, Anal Cancer, Human Papilloma Virus
- Trial name
- NCT03947775
- Testing
- 9-valent HPV vaccination
- Where
- 4 sites in Canada
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Human Papillomavirus-Related Carcinoma
Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants
Human papillomavirus (HPV) is a common sexually-transmitted virus which causes infections that usually last only a few months, but sometimes can last a long time and cause cancers of the cervix, vagina, vulva, anus or oropharynx…
- Trial name
- NCT02568566
- Testing
- Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine
- Where
- 2 sites in United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Human Papilloma Virus, Infertility, Female
Impact of Human Papillomavirus Carriage on IVF/ICSI Results (HPV AMP)
The prevalence of the papilloma virus in the general population is 12%. This virus is known to impair male fertility but its impact on female infertility remains uncertain.
- Trial name
- HPV-AMP (NCT06550531)
- Where
- France
- Volunteers
- 618 people
- Sponsor
- University Hospital, Brest
Genital Warts
Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)
This study is designed to demonstrate non-inferior immunogenicity of 3 doses of the 9-Valent Human Papillomavirus (9vHPV) vaccine (GARDASIL™9, V503) in Chinese males 9 through 19 years of age, and 2 doses of the 9vHPV vaccine in…
- Trial name
- NCT05314023
- Testing
- 9vHPV vaccine
- Where
- 5 sites in China
- Volunteers
- 1,590 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Intraepithelial Neoplasia, Human Papilloma Virus
Local Hyperthermia for the Treatment of Cervical Intraepithelial Neoplasias
Human papillomavirus(HPV) infect epithelial cells and have the capacity to stimulate cell abnormal hyperplasia, especially by those high-risk HPV types.
- Trial name
- HPV (NCT03436251)
- Testing
- Local Hyperthermia at 37℃, LEEP or cold knife, Local Hyperthermia at 44℃
- Where
- China
- Volunteers
- 53 people
- Sponsor
- First Hospital of China Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.